Risk factor
Poor trading liquidity
Profitability factor
Greatly undervalued vs peers
About
Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. It offers ichroma II, an automatic or semiautomatic in-vitro diagnostic device that measures the concentration of analytes, contained in blood, urine, or other samples, in quantitative, or semi-quantitative ways; automated fluorescent immunoassay systems under AFIAS-6 and AFIAS-1 names that uses blood, urine, and other...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD
Target Price
The average target price of 206640.KQ is 23000 and suggests 75% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
Buy
Sell